to fight Covid-19 – the latter’s share price has jumped 10-fold since before the pandemic last year. But the technology behind them is very new.
The optimistic scenario for CureVac Chief Executive Franz-Werner Haas is that something other than his core mRNA technology is the culprit. CureVac’s decision not to use a chemical called uridine to boost the mRNA’s duration in the body may explain its less effective vaccine. If so, and if CureVac’s cancer vaccine trials are more positive, then Jefferies analysts reckon the company’s shares could rebound from $49 to $80.
The real doomsday scenario for Haas is if CureVac’s mRNA has flaws. Jefferies reckons fair value following the vaccine revelations is around $45 per share, but mRNA technology accounts for $40 a share. If the cancer vaccine fails, the analyst reckons it could be worth as little as $14 a share. Until those results come in, investors will be on tenterhooks.- German biotechnology company CureVac said on June 16 that its Covid-19 vaccine was only 47% effective in a late-stage trial.
veltcardio Acá se enteraron y van a pedir 6 millones de dosis 😆